bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure
On June 23, 2017, bluebird bio, Inc. (bluebird) will be
conducting meetings with investors in connection with its
announcement of updated clinical data at the 22nd
Congress of the European Hematology Association.As part of these
meetings, bluebird will deliver the slide presentation furnished
to this report as Exhibit 99.1 and which is incorporated by
reference herein.
See Item 8.01 below, which is incorporated by reference herein.
The information in Item 7.01 of this Report on Form 8-K and
Exhibit 99.1 attached hereto is intended to be furnished and
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item 8.01 Other Events
On June 23, 2017, bluebird issued two press releases announcing
updated clinical data from the Northstar-2 and HGB-205 studies of
its LentiGlobin product candidate in transfusion-dependent
-thalassemia and severe sickle cell disease, being presented at
the 22nd Congress of the European Hematology
Association.The full text of bluebirds press releases regarding
the announcements are filed as Exhibits 99.2 and 99.3 to this
Current Report on Form 8-K and is incorporated herein by
reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 99.2 99.3 |
Investor presentation provided by bluebird bio, Inc. on
Press release issued by bluebird bio, Inc. on June 23,
Press release issued by bluebird bio, Inc. on June 23, |
bluebird bio, Inc. ExhibitEX-99.1 2 blue-ex991_39.htm EX-99.1 blue-ex991_39.pptx.htm EHA 2017 June 23,…To view the full exhibit click here About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
